EVOGENE LTD (EVGN)
IL0011050551 - Common Stock
Taking everything into account, EVGN scores 3 out of 10 in our fundamental rating. EVGN was compared to 565 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
EVGN had negative earnings in the past year.
In the past year EVGN has reported a negative cash flow from operations.
In the past 5 years EVGN always reported negative net income.
In the past 5 years EVGN always reported negative operating cash flow.
1.2 Ratios
EVGN has a Return On Assets (-48.49%) which is comparable to the rest of the industry.
With a Return On Equity value of -647.77%, EVGN is not doing good in the industry: 81.64% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.49% | ||
| ROE | -647.77% | ||
| ROIC | N/A |
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EVGN's Gross Margin of 81.42% is amongst the best of the industry. EVGN outperforms 86.63% of its industry peers.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVGN has less shares outstanding
Compared to 5 years ago, EVGN has less shares outstanding
EVGN has a worse debt/assets ratio than last year.
2.2 Solvency
EVGN has an Altman-Z score of -9.90. This is a bad value and indicates that EVGN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.90, EVGN is not doing good in the industry: 75.22% of the companies in the same industry are doing better.
EVGN has a Debt/Equity ratio of 3.47. This is a high value indicating a heavy dependency on external financing.
EVGN's Debt to Equity ratio of 3.47 is on the low side compared to the rest of the industry. EVGN is outperformed by 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.9 |
ROIC/WACCN/A
WACC5.6%
2.3 Liquidity
A Current Ratio of 4.37 indicates that EVGN has no problem at all paying its short term obligations.
EVGN has a Current ratio of 4.37. This is comparable to the rest of the industry: EVGN outperforms 48.48% of its industry peers.
EVGN has a Quick Ratio of 4.24. This indicates that EVGN is financially healthy and has no problem in meeting its short term obligations.
EVGN's Quick ratio of 4.24 is in line compared to the rest of the industry. EVGN outperforms 48.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.24 |
3. Growth
3.1 Past
EVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.00%, which is quite impressive.
Looking at the last year, EVGN shows a very strong growth in Revenue. The Revenue has grown by 290.45%.
EVGN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.37% yearly.
EPS 1Y (TTM)28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.65%
Revenue 1Y (TTM)290.45%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%39.76%
3.2 Future
EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.88% yearly.
The Revenue is expected to grow by 92.80% on average over the next years. This is a very strong growth
EPS Next Y29.85%
EPS Next 2Y15.5%
EPS Next 3Y17.88%
EPS Next 5YN/A
Revenue Next Year172.11%
Revenue Next 2Y90.31%
Revenue Next 3Y92.8%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EVGN's earnings are expected to grow with 17.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.5%
EPS Next 3Y17.88%
5. Dividend
5.1 Amount
EVGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOGENE LTD
NASDAQ:EVGN (11/21/2024, 8:25:26 PM)
After market: 1.55 -0.05 (-3.12%)1.6
-0.05 (-3.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.10M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.49% | ||
| ROE | -647.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y29.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)290.45%
Revenue growth 3Y75.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y